New obesity drugs are trying to out-blockbuster Wegovy and Mounjaro; Nick Leschly departs Bluebird Bio spinout

Taking stock of the drug industry, from the lab to the medicine chest

September 12, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Molly Ferguson for STAT STAT+ | New obesity drugs are in the works trying to out-blockbuster Wegovy and Mounjaro STAT's new Obesity Drug Tracker shows many copycat candidates in development, but a few novel mechanisms too. By Allison DeAngelis and Elaine Chen STAT+ | Here are the dozens of weight loss drugs in development to catch a booming market Our database tracks the new weight loss drugs that could hit the market, novel mechanisms, and which companies are in the hunt. By Elaine Chen and Allison DeAngelis and J. Emory Parker STAT+ | Nick Leschly departs Bluebird Bio spinout amid restructuring, layoffs The spinout, 2Seventy Bio, announced that it is cutting approximately 40% of its workforce, or about 176 employees. By Allison DeAngelis AP Popular nasal decongestant doesn't actually relieve congestion, FDA experts say FDA advisers voted unanimously on Tuesday against the effectiveness of the ingredient found in popular versions of Sudafed and Allegra. By Associated Press Opinion: Patients might finally receive practical information with prescriptions — if the FDA doesn't blow it We are afraid the FDA might blow this opportunity to give patients useful information with poor design and inadequate testing. By Baruch Fischhoff and Steven Woloshin and Tamar Krishnamurti and Barry Dewitt STAT+ | Neurocrine Biosciences drug for congenital adrenal hyperplasia succeeds in late-stage trial The results bringing Neurocrine a step closer to treating patients with a rare and serious set of genetic disorders. By Jonathan Wosen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser